In recent years, controversy has swirled around the treatment of ductal carcinoma in situ (DCIS). At the 2015 San Antonio Breast Cancer Symposium, David Euhus, MD, the chief of breast surgery at Johns Hopkins Hospital, in Baltimore, discussed the need for better prognostic indicators to guide decisions after a DCIS diagnosis.
“The reason to treat is to avoid invasive breast cancer,” said Dr. Euhus, noting that when he talks to patients about risk, he uses a chart he developed